NewLink Genetics Stock Price, News & Analysis (NASDAQ:NLNK)

$7.10 +0.10 (+1.43 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$7.10
Today's Range$6.72 - $7.11
52-Week Range$5.90 - $25.17
Volume619,637 shs
Average Volume740,581 shs
Market Capitalization$263.25 million
P/E Ratio-2.91
Dividend YieldN/A
Beta1.15

About NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:NLNK
CUSIP65151110
Phone+1-515-2965555

Debt

Debt-to-Equity RatioN/A
Current Ratio5.14%
Quick Ratio5.14%

Price-To-Earnings

Trailing P/E Ratio-2.90983606557377
Forward P/E Ratio-2.68
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.77 million
Price / Sales7.36
Cash FlowN/A
Price / CashN/A
Book Value$4.44 per share
Price / Book1.60

Profitability

Trailing EPS($2.44)
Net Income$-85,150,000.00
Net Margins-229.19%
Return on Equity-63.39%
Return on Assets-47.83%

Miscellaneous

Employees122
Outstanding Shares37,080,000

NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Friday, July, 29th. The biotechnology company reported ($1.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $0.35. The biotechnology company had revenue of $2.01 million for the quarter, compared to analyst estimates of $4.81 million. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. View NewLink Genetics' Earnings History.

When will NewLink Genetics make its next earnings announcement?

NewLink Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for NewLink Genetics.

Where is NewLink Genetics' stock going? Where will NewLink Genetics' stock price be in 2018?

6 analysts have issued 12-month price objectives for NewLink Genetics' stock. Their predictions range from $22.00 to $30.00. On average, they expect NewLink Genetics' share price to reach $25.67 in the next year. View Analyst Ratings for NewLink Genetics.

What are Wall Street analysts saying about NewLink Genetics stock?

Here are some recent quotes from research analysts about NewLink Genetics stock:

  • 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (1/4/2018)
  • 2. Cantor Fitzgerald analysts commented, "Path Forward in Melanoma. Indoximod is expected to enter a pivotal Phase III trial in combination with both Keytruda and Opdivo, with a planned enrollment of 600 patients. The trial design aims to compare PD-1 monotherapy to combination treatments, with co-primary endpoints of overall survival (OS) and progression free survival (PFS)." (11/2/2017)
  • 3. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
  • 4. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Who are some of NewLink Genetics' key competitors?

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the folowing people:

  • Charles J. Link Jr. M.D., Chairman of the Board, Chief Executive Officer, Chief Scientific Officer (Age 56)
  • Nicholas N. Vahanian M.D., President (Age 47)
  • John Bell Henneman III, Chief Financial Officer, Secretary (Age 55)
  • Eugene P. Kennedy M.D., Chief Medical Officer (Age 49)
  • Brian Wiley, Chief Commercial Officer (Age 48)
  • Thomas A. Raffin M.D., Lead Independent Director (Age 68)
  • Paolo Pucci, Director (Age 56)
  • Paul R. Edick, Independent Director (Age 62)
  • Ernest J. Talarico III, Independent Director (Age 44)
  • Lota S. Zoth CPA, Independent Director (Age 57)

Who owns NewLink Genetics stock?

NewLink Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Millennium Management LLC (6.33%), BlackRock Inc. (6.23%), Redmile Group LLC (5.65%), Wells Fargo & Company MN (1.01%), Candriam Luxembourg S.C.A. (0.79%) and Geode Capital Management LLC (0.64%). Company insiders that own NewLink Genetics stock include Carl W Langren, Charles J Jr Link and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.

Who sold NewLink Genetics stock? Who is selling NewLink Genetics stock?

NewLink Genetics' stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., TIAA CREF Investment Management LLC, Segall Bryant & Hamill LLC, Ellington Management Group LLC and Spark Investment Management LLC. View Insider Buying and Selling for NewLink Genetics.

Who bought NewLink Genetics stock? Who is buying NewLink Genetics stock?

NewLink Genetics' stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Redmile Group LLC, BlackRock Inc., Amundi Pioneer Asset Management Inc., Vident Investment Advisory LLC, Hudson Bay Capital Management LP, Virtu Financial LLC and Deutsche Bank AG. View Insider Buying and Selling for NewLink Genetics.

How do I buy NewLink Genetics stock?

Shares of NewLink Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NewLink Genetics stock can currently be purchased for approximately $7.10.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $263.25 million and generates $35.77 million in revenue each year. The biotechnology company earns $-85,150,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. NewLink Genetics employs 122 workers across the globe.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 S Loop Dr Ste 5100, AMES, IA 50010-8641, United States. The biotechnology company can be reached via phone at +1-515-2965555 or via email at [email protected]


MarketBeat Community Rating for NewLink Genetics (NLNK)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  444
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NewLink Genetics (NASDAQ:NLNK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.002.60
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.67$25.67$25.67$19.40
Price Target Upside: 203.57% upside203.57% upside174.22% upside191.29% upside

NewLink Genetics (NASDAQ:NLNK) Consensus Price Target History

Price Target History for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ:NLNK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Cantor FitzgeraldSet Price TargetBuy$26.00LowView Rating Details
11/3/2017Jefferies GroupLower Price TargetBuy$26.00 -> $25.00N/AView Rating Details
11/3/2017Stifel NicolausBoost Price TargetBuy$25.00 -> $29.00N/AView Rating Details
10/13/2017Bank of AmericaInitiated CoverageBuy$22.00N/AView Rating Details
9/8/2017Robert W. BairdUpgradeNeutral -> Outperform$8.00 -> $22.00MediumView Rating Details
3/30/2017SunTrust BanksUpgradeHold -> Buy$12.00 -> $30.00HighView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

NewLink Genetics (NASDAQ:NLNK) Earnings History and Estimates Chart

Earnings by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ NLNK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018        
11/2/2017Q3 2017($0.74)($0.69)$2.38 million$5.48 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.78)($0.57)$2.65 million$10.37 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.46)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)$0.33 million$0.29 millionViewN/AView Earnings Details
11/11/2013Q3($0.33)($0.32)$0.33 million$0.27 millionViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.23 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.30 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.33)($0.30)ViewN/AView Earnings Details
10/31/2012Q3 2012($0.32)($0.28)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.31)($0.31)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.36)($0.24)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.36)($0.44)ViewN/AView Earnings Details
12/16/2011Q3 2011($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

NewLink Genetics (NASDAQ:NLNK) Earnings Estimates

2018 EPS Consensus Estimate: ($2.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.63)($0.63)($0.63)
Q2 20181($0.66)($0.66)($0.66)
Q3 20181($0.69)($0.69)($0.69)
Q4 20181($0.63)($0.63)($0.63)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for NewLink Genetics (NASDAQ:NLNK)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NewLink Genetics (NASDAQ NLNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 54.58%
Insider Trades by Quarter for NewLink Genetics (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics (NASDAQ:NLNK)

NewLink Genetics (NASDAQ NLNK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2017Carl W. LangrenInsiderSell2,229$9.05$20,172.45View SEC Filing  
10/6/2017Stine Seed Farm, Inc.Major ShareholderBuy780,487$10.25$7,999,991.757,857,732View SEC Filing  
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00297,756View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00342,756View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.0519,942View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.1513,465View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06342,756View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.5062,316View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00371,118View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00371,118View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NewLink Genetics (NASDAQ NLNK) News Headlines

Source:
DateHeadline
Nektar And Bristol-Myers Squibbs Deal Could Be An Opportunity For NewLink - Seeking AlphaNektar And Bristol-Myers Squibb's Deal Could Be An Opportunity For NewLink - Seeking Alpha
seekingalpha.com - February 21 at 8:22 AM
Financial Review: RXi Pharmaceuticals (RXII) vs. NewLink Genetics (NLNK)Financial Review: RXi Pharmaceuticals (RXII) vs. NewLink Genetics (NLNK)
www.americanbankingnews.com - February 17 at 12:22 PM
NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018
finance.yahoo.com - February 16 at 5:17 PM
Critical Survey: NewLink Genetics (NLNK) and BIO-TECHNE (TECH)Critical Survey: NewLink Genetics (NLNK) and BIO-TECHNE (TECH)
www.americanbankingnews.com - February 12 at 5:12 PM
NewLink Genetics Corp (NLNK) Given Average Rating of "Buy" by BrokeragesNewLink Genetics Corp (NLNK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 10 at 1:38 PM
Stocks To Watch: Digging For Gems In The ShakeoutStocks To Watch: Digging For Gems In The Shakeout
seekingalpha.com - February 10 at 9:47 AM
NewLink Genetics Corp (NLNK) Expected to Announce Quarterly Sales of $2.72 MillionNewLink Genetics Corp (NLNK) Expected to Announce Quarterly Sales of $2.72 Million
www.americanbankingnews.com - February 9 at 6:20 AM
 Brokerages Expect NewLink Genetics Corp (NLNK) to Announce -$0.69 Earnings Per Share Brokerages Expect NewLink Genetics Corp (NLNK) to Announce -$0.69 Earnings Per Share
www.americanbankingnews.com - February 7 at 1:12 AM
NewLink Genetics to Participate in Upcoming Investor ConferencesNewLink Genetics to Participate in Upcoming Investor Conferences
feeds.benzinga.com - February 6 at 9:27 AM
NewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.72 MillionNewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.72 Million
www.americanbankingnews.com - January 23 at 12:56 PM
NewLink Genetics Corp (NLNK) Expected to Post Earnings of -$0.69 Per ShareNewLink Genetics Corp (NLNK) Expected to Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - January 21 at 3:22 AM
NewLink Genetics Corp (NLNK) Given Average Rating of "Buy" by AnalystsNewLink Genetics Corp (NLNK) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 16 at 1:40 PM
What Do Analysts Think About NewLink Genetics Corporation’s (NASDAQ:NLNK) Earnings Trend?What Do Analysts Think About NewLink Genetics Corporation’s (NASDAQ:NLNK) Earnings Trend?
finance.yahoo.com - January 16 at 9:37 AM
NewLink Genetics (NLNK) Announces 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 InhibitorsNewLink Genetics (NLNK) Announces 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
www.streetinsider.com - January 10 at 9:38 AM
NewLink Genetics Corp Forecasted to Post FY2022 Earnings of ($1.05) Per Share (NLNK)NewLink Genetics Corp Forecasted to Post FY2022 Earnings of ($1.05) Per Share (NLNK)
www.americanbankingnews.com - January 8 at 8:40 PM
Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics CorporationNewman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation
finance.yahoo.com - January 8 at 5:21 PM
NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 InhibitorsNewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors
finance.yahoo.com - January 8 at 9:58 AM
Investors Buy Large Volume of NewLink Genetics Call Options (NLNK)Investors Buy Large Volume of NewLink Genetics Call Options (NLNK)
www.americanbankingnews.com - January 8 at 3:12 AM
Zacks: Brokerages Expect NewLink Genetics Corp (NLNK) Will Announce Quarterly Sales of $2.72 MillionZacks: Brokerages Expect NewLink Genetics Corp (NLNK) Will Announce Quarterly Sales of $2.72 Million
www.americanbankingnews.com - January 6 at 5:36 AM
NewLink Genetics (NLNK) Upgraded to "Hold" at BidaskClubNewLink Genetics (NLNK) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - January 5 at 11:48 PM
 Analysts Anticipate NewLink Genetics Corp (NLNK) Will Post Earnings of -$0.69 Per Share Analysts Anticipate NewLink Genetics Corp (NLNK) Will Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - January 4 at 7:44 AM
NewLink Genetics (NLNK) Stock Rating Lowered by Zacks Investment ResearchNewLink Genetics (NLNK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 4 at 6:04 AM
Zacks Investment Research Upgrades NewLink Genetics (NLNK) to BuyZacks Investment Research Upgrades NewLink Genetics (NLNK) to Buy
www.americanbankingnews.com - January 3 at 1:20 PM
ArQule (ARQL) & NewLink Genetics (NLNK) Head to Head ComparisonArQule (ARQL) & NewLink Genetics (NLNK) Head to Head Comparison
www.americanbankingnews.com - December 26 at 5:48 AM
NewLink Genetics Corp (NLNK) Receives Average Rating of "Buy" from AnalystsNewLink Genetics Corp (NLNK) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - December 22 at 2:18 PM
NewLink Genetics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)NewLink Genetics to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 21 at 9:36 AM
NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare ConferenceNewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 21 at 9:36 AM
Comparing Alkermes (ALKS) & NewLink Genetics (NLNK)Comparing Alkermes (ALKS) & NewLink Genetics (NLNK)
www.americanbankingnews.com - December 19 at 9:32 AM
Zacks: Analysts Expect NewLink Genetics Corp (NLNK) to Post -$0.69 Earnings Per ShareZacks: Analysts Expect NewLink Genetics Corp (NLNK) to Post -$0.69 Earnings Per Share
www.americanbankingnews.com - December 18 at 3:26 PM
Financial Review: NewLink Genetics (NLNK) and Its CompetitorsFinancial Review: NewLink Genetics (NLNK) and Its Competitors
www.americanbankingnews.com - December 12 at 9:26 AM
Reviewing NewLink Genetics (NLNK) and Its RivalsReviewing NewLink Genetics (NLNK) and Its Rivals
www.americanbankingnews.com - December 10 at 3:30 PM
NewLink Genetics to Participate in Upcoming Investor Conference - GlobeNewswire (press release)NewLink Genetics to Participate in Upcoming Investor Conference - GlobeNewswire (press release)
globenewswire.com - November 28 at 10:20 AM
NewLink Genetics Corp (NLNK) Short Interest UpdateNewLink Genetics Corp (NLNK) Short Interest Update
www.americanbankingnews.com - November 28 at 3:02 AM
NewLink Genetics to Participate in Upcoming Investor ConferenceNewLink Genetics to Participate in Upcoming Investor Conference
feeds.benzinga.com - November 27 at 11:07 AM
Carl W. Langren Sells 2,229 Shares of NewLink Genetics Corporation (NLNK) StockCarl W. Langren Sells 2,229 Shares of NewLink Genetics Corporation (NLNK) Stock
www.americanbankingnews.com - November 22 at 9:17 PM
NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for ChildrenNewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children
finance.yahoo.com - November 21 at 8:37 AM
NewLink Genetics Corporation (NLNK) & The Competition Financial ComparisonNewLink Genetics Corporation (NLNK) & The Competition Financial Comparison
www.americanbankingnews.com - November 19 at 3:26 AM
NewLink Genetics Appoints Eugene Kennedy, MD as Chief Medical Officer - GlobeNewswire (press release)NewLink Genetics Appoints Eugene Kennedy, MD as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:48 AM
NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical OfficerNewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer
finance.yahoo.com - November 15 at 6:48 AM
$2.72 Million in Sales Expected for NewLink Genetics Corporation (NLNK) This Quarter$2.72 Million in Sales Expected for NewLink Genetics Corporation (NLNK) This Quarter
www.americanbankingnews.com - November 14 at 10:51 AM
Comparing NewLink Genetics Corporation (NLNK) & Its RivalsComparing NewLink Genetics Corporation (NLNK) & Its Rivals
www.americanbankingnews.com - November 13 at 7:30 PM
NewLink Genetics to Participate in November Investor ConferencesNewLink Genetics to Participate in November Investor Conferences
finance.yahoo.com - November 13 at 4:55 PM
Zacks: Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Announce Earnings of -$0.69 Per ShareZacks: Brokerages Anticipate NewLink Genetics Corporation (NLNK) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - November 12 at 3:42 AM
FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)FY2017 EPS Estimates for NewLink Genetics Corporation Raised by Cantor Fitzgerald (NLNK)
www.americanbankingnews.com - November 8 at 11:24 AM
NewLink Genetics Corporation to Post Q1 2018 Earnings of ($0.63) Per Share, SunTrust Banks Forecasts (NLNK)NewLink Genetics Corporation to Post Q1 2018 Earnings of ($0.63) Per Share, SunTrust Banks Forecasts (NLNK)
www.americanbankingnews.com - November 6 at 10:03 AM
Brokers Set Expectations for NewLink Genetics Corporations FY2017 Earnings (NLNK)Brokers Set Expectations for NewLink Genetics Corporation's FY2017 Earnings (NLNK)
www.americanbankingnews.com - November 6 at 3:48 AM
NewLink Genetics Corporation (NLNK) Given New $25.00 Price Target at Jefferies Group LLCNewLink Genetics Corporation (NLNK) Given New $25.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - November 5 at 8:46 AM
NewLink Genetics (NLNK) CEO Charles Link on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaNewLink Genetics' (NLNK) CEO Charles Link on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 4 at 3:46 PM
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program - GlobeNewswire (press release)NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program - GlobeNewswire (press release)
globenewswire.com - November 4 at 8:05 AM
NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod ProgramNewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program
finance.yahoo.com - November 4 at 8:05 AM

SEC Filings

NewLink Genetics (NASDAQ:NLNK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NewLink Genetics (NASDAQ:NLNK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NewLink Genetics (NASDAQ NLNK) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.